Compare CMPS & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMPS | DCTH |
|---|---|---|
| Founded | 2020 | 1988 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 598.7M | 289.2M |
| IPO Year | 2020 | N/A |
| Metric | CMPS | DCTH |
|---|---|---|
| Price | $6.78 | $10.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $16.43 | ★ $22.60 |
| AVG Volume (30 Days) | ★ 1.6M | 739.3K |
| Earning Date | 11-04-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.03 |
| Revenue | N/A | ★ $79,603,000.00 |
| Revenue This Year | N/A | $131.97 |
| Revenue Next Year | N/A | $38.84 |
| P/E Ratio | ★ N/A | $300.67 |
| Revenue Growth | N/A | ★ 251.54 |
| 52 Week Low | $2.25 | $8.12 |
| 52 Week High | $7.13 | $18.23 |
| Indicator | CMPS | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 66.43 | 62.85 |
| Support Level | $4.90 | $9.59 |
| Resistance Level | $5.57 | $10.14 |
| Average True Range (ATR) | 0.38 | 0.44 |
| MACD | 0.20 | 0.16 |
| Stochastic Oscillator | 84.53 | 87.15 |
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.